Product How it works Pricing Blog FAQ About Contact
Solid Biosciences

Solid Biosciences (NASDAQ: SLDB) net income

Solid Biosciences reported a net loss of $174.3m for fiscal 2025; in fiscal 2024 it reported a net loss of $124.7m. Earnings per share were −$1.99.

Solid Biosciences's best year of the last 9 was fiscal 2017. It reported a loss in 9 of those 9 years.

Net income, in millions of US dollars-52.12017-74.82018-117.22019-88.32020-72.22021-86.02022-96.02023-124.72024-174.32025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Net income by fiscal year

Fiscal yearNet incomeChangeNet marginEarnings per share
2025−$174.3m——−$1.99
2024−$124.7m——−$3.06
2023−$96.0m——−$4.83
2022−$86.0m—−1,062.3%−$10.10
2021−$72.2m—−530.0%−$10.14
2020−$88.3m——−$25.50
2019−$117.2m———
2018−$74.8m———
2017−$52.1m———

The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Solid Biosciences net income compared with its sector

By net income for its latest fiscal year, Solid Biosciences ranks 399th of the 501 US health care companies with a page on Celsmar.

RankCompanyNet incomeNet margin
397thARS Pharmaceuticals−$171.3m−203.3%
398thArmata Pharmaceuticals−$173.8m—
399thSolid Biosciences−$174.3m—
400thZai Lab−$175.5m−38.1%
401stCelcuity−$177.0m—

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the net income of Solid Biosciences

How much did Solid Biosciences earn in fiscal 2025?
Solid Biosciences reported a net loss of $174.3m for fiscal 2025. In fiscal 2024 it reported a net loss of $124.7m.
What are the earnings per share of Solid Biosciences?
They were −$1.99 in fiscal 2025, compared with −$3.06 in fiscal 2024.
Where does Solid Biosciences rank in its sector by net income?
It ranks 399th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
Where do the figures for Solid Biosciences come from?
From the annual report (Form 10-K) that Solid Biosciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Solid Biosciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017. More on Solid Biosciences: the Solid Biosciences page · annual accounts · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.